Robert A. Gabbay, MD, PhD, FACP

The editor-in-chief of Evidence-Based Diabetes Management™ introduces the special issue, Perspectives on Insulin Pricing, and shares that he has seen rationing among his own patients.

Evidence that newer type 2 diabetes therapies offer cardiovasular and renal benefits offer opportunities for greater collaboration among specialists and more value for patients. Payers must take notice.

From the Editor in Chief of Evidence-Based Diabetes Management.™ Dr Gabbay is senior vice presdient and chief medical officer of Joslin Diabetes Center in Boston, Massachusetts.

From the Adult Diabetes and Clinical Research Sections, Joslin Diabetes Center, Harvard Medical School. Approved May 10, 2016; updated April 24, 2018. For the Figure and Tables, download the PDF at the end of the chapter.

From the Adult Diabetes and Clinical Research sections, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts. This guideline was revised and approved May 17, 2017, and updated February 7, 2018.

From the Adult Diabetes and Clinical Research sections, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts

From the Adult Diabetes and Clinical Research sections, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.

From the Adult Diabetes and Clinical Research sections, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.

Listed below are members of the Clinical Oversight Committee and Working Groups who participated in development of the Clinical Guidelines for Joslin Diabetes Center. Faculty who participated in guideline development who are no longer at Joslin are designated with an asterisk.

Om P. Ganda, MD, serves as chair of the Joslin Clinical Oversight Committee, and Robert A. Gabbay, MD, PhD, FACP, is senior vice president and chief medical officer of Joslin Diabetes Center.

A commentary from our editor-in-chief on the recent guidance from the American College of Physicians regarding glycemic control for adults with type 2 diabetes.

From the Editor in Chief

From the Editor-in-Chief

Five-year results of the Why WAIT study at Joslin Diabetes Center.

The 2015 joint statement of the American Association of Diabetes Educators, the American Diabetes Association, and the Academy of Nutrition and Dietetics called for diabetes self-management education and support at 4 distinct points: at diagnosis, at annual assessments, when complications arise, and at transitions.

Robert A. Gabbay, MD, PhD, FACP, editor-in-chief of Evidence-Based Diabetes Management, discusses the complexities of the current debate over the cost of insulin.

Dr Gabbay is editor in chief of Evidence-Based Diabetes Management.

An introduction to the Joslin Clinical Analytic Tool, a new diabetes measure developed to adjust for the variety in patient mix and better inform clinicians which interventions will work best.

Joslin Diabetes Center has earned the highest level of recognition from the National Committee for Quality Assurance, which cited the center's strengths in communication, access, and coordination of care in the citation for a Patient-Centered Specialty Practice.